阿巴西普用于类风湿关节炎高风险个体(APIPPRA):一项随机、双盲、多中心、平行、安慰剂对照的2b期临床试验
APIPPRA试验纳入28家英国和3家荷兰医院早期关节炎门诊中抗环瓜氨酸蛋白抗原抗体(ACPA)和类风湿因子阳性伴炎性关节痛的高风险个体,随机分配接受阿巴西普125 mg皮下注射每周一次或安慰剂治疗12个月并随访12个月。阿巴西普组12个月无关节炎生存比例92.8%(SE 2.6)vs 安慰剂组69.2%(SE 4.7),24个月进展为类风湿关节炎27/110(25%)vs 38/103(37%)。作者认为在高风险期干预可行、安全性可接受,阿巴西普12个月降低进展且疗效持续至治疗期后,无新安全信号。
要点
- 阿巴西普组12个月无关节炎生存比例92.8% vs 安慰剂组69.2%。
- 24个月进展为类风湿关节炎:阿巴西普组25% vs 安慰剂组37%。
- 治疗期疼痛、功能、生活质量及超声亚临床滑膜炎改善,但24个月未持续。
核心结论
- 在类风湿关节炎高风险期进行干预可行且安全性可接受;阿巴西普12个月降低进展为类风湿关节炎,疗效持续至治疗期后且无新安全信号。
研究设计与样本
- 随机、双盲、多中心、平行、安慰剂对照2b期临床试验,在英国28家和荷兰3家医院早期关节炎门诊开展。
- 纳入年龄≥18岁、ACPA和类风湿因子阳性伴炎性关节痛的高风险个体;排除既往临床滑膜炎及既往使用糖皮质激素或改善病情抗风湿药者。
- 按1:1计算机生成置换区组随机(区组大小2和4),按性别、吸烟和国家分层,分配至阿巴西普125 mg皮下注射每周一次或安慰剂治疗12个月,随后随访12个月。
主要发现
- 治疗期达到主要终点者:阿巴西普组7/110(6%)vs 安慰剂组30/103(29%)。
- 24个月进展为类风湿关节炎者:阿巴西普组27/110(25%)vs 安慰剂组38/103(37%)。
- 12个月估计无关节炎生存比例:阿巴西普组92.8%(SE 2.6)vs 安慰剂组69.2%(SE 4.7)。
- 24个月Kaplan-Meier无关节炎生存曲线支持阿巴西普(log-rank检验p=0.044)。
- 限制性平均生存时间组间差异:12个月53天(95%CI 28-78;p<0.0001),24个月99天(95%CI 38-161;p=0.0016),均支持阿巴西普。
关键数值与推荐
- 主要终点为3个或以上关节临床滑膜炎或符合美国风湿病学会和欧洲抗风湿病联盟2010标准类风湿关节炎的时间,以先发生者为准,滑膜炎经超声确认。
- 治疗期阿巴西普组疼痛评分、功能健康状态及生活质量测量改善,超声亚临床滑膜炎评分低,但24个月时效应未持续。
- 严重不良事件:阿巴西普组7例,安慰剂组11例,包括每组1例死亡,均判定与治疗无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Individuals with serum antibodies to citrullinated protein antigens (ACPA), rheumatoid factor, and symptoms, such as inflammatory joint pain, are at high risk of developing rheumatoid arthritis. In the arthritis prevention in the pre-clinical phase of rheumatoid arthritis with abatacept (APIPPRA) trial, we aimed to evaluate the feasibility, efficacy, and acceptability of treating high risk individuals with the T-cell co-stimulation modulator abatacept. METHODS: The APIPPRA study was a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial done in 28 hospital-based early arthritis clinics in the UK and three in the Netherlands. Participants (aged ≥18 years) at risk of rheumatoid arthritis positive for ACPA and rheumatoid factor with inflammatory joint pain were recruited. Exclusion criteria included previous episodes of clinical synovitis and previous use of corticosteroids or disease-modifying antirheumatic drugs. Participants were randomly assigned (1:1) using a computer-generated permuted block randomisation (block sizes of 2 and 4) stratified by sex, smoking, and country, to 125 mg abatacept subcutaneous injections weekly or placebo for 12 months, and then followed up for 12 months. Masking was achieved by providing four kits (identical in appearance and packaging) with pre-filled syringes with coded labels of abatacept or placebo every 3 months. The primary endpoint was the time to development of clinical synovitis in three or more joints or rheumatoid arthritis according to American College of Rheumatology and European Alliance of Associations for Rheumatology 2010 criteria, whichever was met first. Synovitis was confirmed by ultrasonography. Follow-up was completed on Jan 13, 2021. All participants meeting the intention-to-treat principle were included in the analysis. This trial was registered with EudraCT (2013-003413-18). FINDINGS: Between Dec 22, 2014, and Jan 14, 2019, 280 individuals were evaluated for eligibility and, of 213 participants, 110 were randomly assigned to abatacept and 103 to placebo. During the treatment period, seven (6%) of 110 participants in the abatacept group and 30 (29%) of 103 participants in the placebo group met the primary endpoint. At 24 months, 27 (25%) of 110 participants in the abatacept group had progressed to rheumatoid arthritis, compared with 38 (37%) of 103 in the placebo group. The estimated proportion of participants remaining arthritis-free at 12 months was 92·8% (SE 2·6) in the abatacept group and 69·2% (4·7) in the placebo group. Kaplan-Meier arthritis-free survival plots over 24 months favoured abatacept (log-rank test p=0·044). The difference in restricted mean survival time between groups was 53 days (95% CI 28-78; p<0·0001) at 12 months and 99 days (95% CI 38-161; p=0·0016) at 24 months in favour of abatacept. During treatment, abatacept was associated with improvements in pain scores, functional wellbeing, and quality-of-life measurements, as well as low scores of subclinical synovitis by ultrasonography, compared with placebo. However, the effects were not sustained at 24 months. Seven serious adverse events occurred in the abatacept group and 11 in the placebo group, including one death in each group deemed unrelated to treatment. INTERPRETATION: Therapeutic intervention during the at-risk phase of rheumatoid arthritis is feasible, with acceptable safety profiles. T-cell co-stimulation modulation with abatacept for 12 months reduces progression to rheumatoid arthritis, with evidence of sustained efficacy beyond the treatment period, and with no new safety signals. FUNDING: Bristol Myers Squibb.
引用
- Cope AP, Jasenecova M, Vasconcelos JC, et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet. 2024. PMID: 38364839. doi:10.1016/S0140-6736(23)02649-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。